Collin Hovinga
Vice President - Rare & Orphan Diseases CPATH
Collin Hovinga, PharmD, MS, FCCP, serves as Vice President of the Rare and Orphan Disease Programs at the Critical Path Institute overseeing C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform and the Critical Path for Rare Neurodegenerative Diseases public-private partnership. Dr. Hovinga completed his Bachelor of Science Degree in Biology and Doctor of Pharmacy degrees from Creighton University in Omaha, Nebraska. After which he pursued a Residency and Fellowship in Pediatric Pharmacotherapy with emphasis in Pediatric Neuroscience at the University of Tennessee, Memphis, LeBonheur Children’s Medical Center. He has had a Fellowship at the Food and Drug Administration Office of Clinical Pharmacology and a Masters of Epidemiology from the University of Tennessee Health Science Center. Dr. Hovinga has been active in studying factors that influence the efficacy, safety, and the pharmacology of antiepileptic drugs in children, patient adherence to medications, and acute seizure management. Dr. Hovinga is recognized as an expert in neuropharmacology.
Seminars
This interactive workshop will explore how clinical trial endpoints can be designed to reflect what truly matters to people living with ALS. Participants will discuss strategies for integrating patient-reported outcomes, functional measures, digital biomarkers, and quality of-life metrics into trial design. The session will highlight collaborative approaches with patient advocacy groups, lessons from ongoing studies, and regulatory considerations for demonstrating clinical meaningfulness. Attendees will gain practical insights into creating endpoints that enhance trial relevance, patient engagement, and therapeutic impact.
Key Discussion Points
- Defining endpoints that capture functional, cognitive, and quality-of-life outcomes meaningful to patients
- Incorporating patient-reported outcomes, digital tools, and real-world data into trial design
- Regulatory perspectives on patient-centered endpoints and demonstrating clinical relevance
- Collaborative models to co-design endpoints with patients and advocacy groups
